Dexrazoxane: A promising antidote in the treatment of accidental extravasation of anthracyclinesJENSEN, Jesper Nested; LOCK-ANDERSEN, Jørgen; LANGER, Seppo W et al.Scandinavian journal of plastic and reconstructive surgery and hand surgery. 2003, Vol 37, Num 3, pp 174-175, issn 0284-4311, 2 p.Article

Successful Experience Utilizing Dexrazoxane Treatment for an Anthracycline ExtravasationMERCER TYSON, Abby; GAY, Wendy E.The Annals of pharmacotherapy. 2010, Vol 44, Num 5, pp 922-925, issn 1060-0280, 4 p.Article

Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187)SCHROEDER, Patricia E; DAVIDSON, Jeffrey N; HASINOFF, Brian B et al.Drug metabolism and disposition. 2002, Vol 30, Num 12, pp 1431-1435, issn 0090-9556, 5 p.Article

Clinical pharmacology of dexrazoxaneHOCHSTER, H. S.Seminars in oncology. 1998, Vol 25, Num 4, pp 37-42, issn 0093-7754, SUP10Article

Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphomaLIMAT, S; DAGUINDAU, E; CAHN, J.-Y et al.Journal of clinical pharmacy and therapeutics (Print). 2014, Vol 39, Num 2, pp 168-174, issn 0269-4727, 7 p.Article

Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: Anti-apoptosis and promoting angiogenesisLIGANG ZHOU; TZ SUNG, Rita Yn; KAREN LI et al.International journal of cardiology. 2011, Vol 152, Num 2, pp 196-201, issn 0167-5273, 6 p.Article

Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxaneATTIA, Sabry M; AL-ANTEET, Alaa A; AI-RASHEED, Nouf M et al.Cancer chemotherapy and pharmacology. 2009, Vol 64, Num 4, pp 837-845, issn 0344-5704, 9 p.Article

dexrazoxane ^(SAVENE°) : Extravasation d'anthracycline : en rester au diméthylsulfoxyde = Dexrazoxane for anthracycline extravasation : better retaining dimethylsulfoxideLa Revue Prescrire. 2008, Vol 28, Num 301, pp 816-816, issn 0247-7750, 1 p.Article

Subacute cardiotoxicity caused by anthracycline therapy in children : can dexrazoxane prevent this effect?KOVACS, Gabor T; ERLAKY, Hajna; TOTH, Kornélia et al.European journal of pediatrics. 2007, Vol 166, Num 11, pp 1187-1188, issn 0340-6199, 2 p.Article

Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumorsHOFLAND, Kenneth Francis; THOUGAARD, Annemette Vinding; DEJLIGBJERG, Marielle et al.Clinical cancer research. 2005, Vol 11, Num 18, pp 6722-6729, issn 1078-0432, 8 p.Article

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel reviewSWAIN, S. M; VICI, P.Journal of cancer research and clinical oncology. 2004, Vol 130, Num 1, pp 1-7, issn 0171-5216, 7 p.Article

Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposideSCHROEDER, Patricia E; JENSEN, Peter Buhl; SEHESTED, Maxwell et al.Cancer chemotherapy and pharmacology. 2003, Vol 52, Num 2, pp 167-174, issn 0344-5704, 8 p.Article

In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy : time to consider expanded clinical trials?BUDMAN, D. R; CALABRO, A; KREIS, W et al.Leukemia. 2001, Vol 15, Num 10, pp 1517-1520, issn 0887-6924Article

The effect of the catalytic topoisomerase II inhibitor dexrazoxane (ICRF-187) on CC9C10 hybridoma viability and productivityBARNABE, Norman; BUTLER, Michael; HASINOFF, Brian B et al.Cytotechnology (Dordrecht). 2001, Vol 37, Num 2, pp 107-117, issn 0920-9069Article

Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH₂-Terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cellsKHELIFA, T; BECK, W. T.Biochemical pharmacology. 1999, Vol 58, Num 8, pp 1247-1257, issn 0006-2952Article

Preclinical animal models of cardiac protection from anthracycline-lnduced cardiotoxicityHERMAN, E. H; FERRANS, V. J.Seminars in oncology. 1998, Vol 25, Num 4, pp 15-21, issn 0093-7754, SUP10Article

Phase I trials of dexrazoxane and other potential applications for the agentVON HOFF, D. D.Seminars in oncology. 1998, Vol 25, Num 4, pp 31-36, issn 0093-7754, SUP10Article

Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinationsSPARANO, J. A.Seminars in oncology. 1998, Vol 25, Num 4, pp 66-71, issn 0093-7754, SUP10Article

Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase IIHASINOFF, B. B; KUSCHAK, T. I; CREIGHTON, A. M et al.Biochemical pharmacology. 1997, Vol 53, Num 12, pp 1843-1853, issn 0006-2952Article

Dexrazoxane Prevents the Development of the Impaired Cardiac Phenotype in Caveolin-1-disrupted MicePOLANSKI, Anne-Katrin; EBNER, Annette; WUNDERLICH, Carsten et al.Journal of cardiovascular pharmacology. 2013, Vol 61, Num 6, pp 545-552, issn 0160-2446, 8 p.Article

Extravasation of Liposomal Doxorubicin Induces Irritant Reaction without Vesicant InjuryCURTIT, Elsa; CHAIGNEAU, Loic; PAUCHOT, Julien et al.Anticancer research. 2012, Vol 32, Num 4, pp 1481-1483, issn 0250-7005, 3 p.Article

Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxaneLANGER, Seppo W; THOUGAARD, Annemette V; SEHESTED, Maxwell et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 2, pp 573-576, issn 0344-5704, 4 p.Article

Antimuscarinic action of doxorubicin does not involve free-radical formation in isolated guinea pig heartsSASAKI, Takushi; UENO, Shunji; HARA, Yukio et al.Canadian journal of physiology and pharmacology. 2010, Vol 88, Num 1, pp 77-81, issn 0008-4212, 5 p.Article

Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With DexrazoxaneBARRY, Elly V; VROOMAN, Lynda M; SCHORIN, Marshall A et al.Journal of clinical oncology. 2008, Vol 26, Num 7, pp 1106-1111, issn 0732-183X, 6 p.Article

Dexrazoxane ^{(cardioxane°)} : PRÉVENTION DE LA CARDIOTOXICITÉ DES ANTHRACYCLINES, AVEC DU RECUL : POUR QUELQUES MALADES = Dexrazoxane for anthracyclins cardiotoxicity prevention : a critical studyLa Revue Prescrire. 2008, Vol 28, Num 293, pp 175-175, issn 0247-7750, 1 p.Article